• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chiltern acquires Ockham, strengthening oncology, CRO services, job placement

Chiltern acquires Ockham, strengthening oncology, CRO services, job placement

July 15, 2014
CenterWatch Staff

U.K.-based Chiltern, a 32-year-old global CRO specializing in oncology services and a range of other therapeutic areas, has acquired Ockham, a 28-year-old oncology-focused CRO, and the two companies will merge their operations.

Terms of the deal were not disclosed. 

The combined company—both have operations in North Carolina—will be called Chiltern, and Ockham’s management will join the leadership of the enlarged entity. Chiltern’s CEO, Jim Esinhart, Ph.D., will be CEO of the Chiltern Group, with James V. Baker, Ockham’s CEO, becoming chief development officer.

“In Ockham’s continuing progression toward building the top niche oncology CRO, our joining with Chiltern has been an easy choice, allowing us to leverage Chiltern’s global reach and highly developed staffing business in Europe, both of which are complementary to Ockham’s deep oncology expertise and source business in the U.S.,” said Baker in a prepared statement. “We are fortunate to have found the ideal partner with a complete understanding and commitment of the unique needs of our emerging biotech clientele.”

Calling the deal a complementary transaction, the companies said the merger will strengthen combined service offerings in three strategic areas:

  • Oncology specialization with expertise across all clinical phases of development, known as Chiltern Oncology;
  • Biopharmaceutical services with global reach and scale, including deep therapeutic experience in respiratory, ophthalmology, infectious disease, vaccines and dermatology, known as Chiltern Biopharmaceuticals; and
  • Global Functional Service Provider (FSP) /Sourcing provision specializing in helping people find employment across clinical, regulatory, medical and biometric areas, known as Chiltern Source.

Chiltern said the combined company will provide services across a global network of offices and expertise.

“The merger is a natural progression toward our strategic goal of becoming the premier specialized mid-tier CRO,” Esinhart said in a prepared statement.  “There is a perfect strategic fit between our companies, and I’m excited to work with the entire Ockham team to ensure a seamless continuation in the delivery of high-quality services to all of the combined company’s clients.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing